Abstract
BackgroundMany studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). This study is a meta-analysis of available evidence.MethodsFifteen studies reporting Endostar combined with PBDC versus PBDC alone for treating advanced NSCLC were reviewed. Pooled odds ratios and hazard ratio with 95% confidence intervals were calculated using either the fixed effects model or random effects model.ResultsThe overall response rate (ORR) and disease control rate (DCR) of Endostar combined with PBDC for treating NSCLC were significantly higher than those of PBDC alone, with 14.7% and 13.5% improvement, respectively (P < 0.00001). In addition, the time to progression (TTP) and quality of life (QOL) were improved after the treatment of Endostar combined with PBDC (P < 0.00001). The main adverse effects found in this review were hematological reactions, hepatic toxicity, and nausea/vomiting. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone (P < 0.05).ConclusionsEndostar combined with PBDC was associated with higher RR, DCR, and TTP as well as superior QOL profiles compared with PBDC alone. Endostar combined with PBDC had a similar incidence of adverse reactions compared with PBDC alone.
Highlights
Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC)
Compared with rh-endostatin reported in previous literature, an additional nine-amino acid sequence (MGGSHHHHH) was added at the N-terminal of the protein, which resulted in the formation of a sixhistidine tag that could be chelated with metal ions such as Ni2+ with a relatively high affinity
The current study presents a systematic review to quantify the toxicities and clinical benefits of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus chemotherapy alone for treating advanced NSCLC
Summary
Many studies have investigated the efficacy of Endostar combined with platinum-based doublet chemotherapy (PBDC) versus PBDC alone for treating advanced non-small cell lung cancer (NSCLC). Compared with rh-endostatin reported in previous literature, an additional nine-amino acid sequence (MGGSHHHHH) was added at the N-terminal of the protein, which resulted in the formation of a sixhistidine tag that could be chelated with metal ions such as Ni2+ with a relatively high affinity. These changes simplified the purification and improved the stability of the protein [7,8]. The effect of the structural changes on the antiangiogenic efficacy, including the mechanism of action, remains unknown
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
